secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001815776-26-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENZ Q4 2025 prelim product rev $1.6M; >20K prescriptions for VIZZ launch
-------------------------------------------------------------------------

- Net product revenue of ~$1.6M from VIZZ in first launch quarter (Q4 2025), with over 20,000 prescriptions filled.
- Over 6,500 unique eye care professionals prescribed VIZZ; more than 55% prescribed multiple times in Q4.
- VIZZ launched October 2025; broad retail and epharmacy access achieved by mid-November 2025.
- Announced fourth international commercialization partnership with Lunatus for Middle East with milestones and revenue share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000181577626000003/0001815776-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000181577626000003/lenz-20260107.htm
  HTML page:      https://secwatch.observer/filing/0001815776-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer